Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

9
TESARO to Announce Second-Quarter 2018 Financial Results on August 2, 2018

2018-07-20 globenewswire
WALTHAM, Mass., July 20, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO) will announce second-quarter 2018 financial results on Thursday, August 2, 2018, after the close of the U.S. financial markets. TESARO’s senior management team will host a conference call and live audio webcast at 4:15 p.m. ET on August 2, 2018 to discuss the Company’s operating results for the quarter in greater detail, as well as the status of its development programs.
TSRO

9
TSRO / TESARO, Inc. 8-K (Current Report)

2018-07-18 sec.gov
UNITED STATES
TSRO

15
Rounds Report: The Strong Rally Of Galmed Is Reflective Of Aramchol's Prospects

2018-07-13 seekingalpha
The overall bioscience market traded with the strong confidence going into the weekend. Many equities under our coverage continue to rally and thereby procured increasing profits for shareholders.
TSRO OPK GLMD BRLI IBB XBI PFE

9
Evaluation Of Tesaro: Fair Value And Acquisition Potential

2018-07-12 seekingalpha
Editor's note: Seeking Alpha is proud to welcome Pharmyang Investment as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more »
TSRO

9
TSRO / TESARO, Inc. null

2018-07-11 sec.gov
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C$P(# @;V)J#3P\+TQI;F5A#0IE;F1S M=')E86T-96YD;V)J#7-T87)T>')[email protected]*, T*)25%3T8-"B @(" @(" @#0HR M,B P(&]B:@T\/"]&:6QT97(O1FQA=&5$96-O9&4O22 X-"],(#8X+TQE;F=T M:" V,2]3(#,X/CYS=')E86T-"FC>[email protected][email protected]
TSRO

10
TSRO / TESARO, Inc. / FMR LLC / Fidelity - null (Passive Investment)

2018-07-10 sec.gov
SCHEDULE 13G Amendment No. 6 TESARO INC COMMON STOCK Cusip #881569107 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #881569107 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 550,034 Item 6: 0 Item 7: 5,286,055 Item 8: 0 Item 9: 5,286,055 Item 11: 9.641% Item 12: HC Cusip #881569107 Item 1: Reporting Person - Abigail P.
TSRO

14
TSRO / TESARO, Inc. / FMR LLC / Fidelity - null (Passive Investment)

2018-07-10 sec.gov
SCHEDULE 13G Amendment No. 6 TESARO INC COMMON STOCK Cusip #881569107 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #881569107 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 550,034 Item 6: 0 Item 7: 5,286,055 Item 8: 0 Item 9: 5,286,055 Item 11: 9.641% Item 12: HC Cusip #881569107 Item 1: Reporting Person - Abigail P.
TSRO

13
Clovis Gets EU Acceptance for Rubraca Label Expansion Filing

2018-07-06 zacks
Clovis Oncology, Inc. (CLVS - Free Report) announced that the European Medicines Agency ("EMA") has accepted its type II variation to the marketing authorization seeking label expansion of Rubraca in Europe.
TSRO AZN AZN PFE CLVS

10
TESARO Partners With the Pan-Mass Challenge for 2018 Ride Benefiting Dana-Farber Cancer Institute

2018-07-02 globenewswire
WALTHAM, Mass., July 02, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, is proud to announce a new partnership supporting the Pan-Mass Challenge (PMC). The PMC is the nation’s most successful athletic fundraising event, raising money for cancer research and treatment at Dana-Farber Cancer Institute through a yearly bike-a-thon that crosses the Commonwealth of Massachusetts.
TSRO

57
Biopharma Companies to Watch This Week

2018-07-01 247wallst
Companies in the biotech and pharmaceutical industries are subject to a sizable amount of risk with regards to their drug candidates passing clinical trials and gaining regulatory approval. But with the risk of failure, which could spell disaster for a stock, comes great reward as well. Some companies can see a massive upside just from winning a single midstage trial or even achieving as much as a Fast Track designation from the U.
OMER TSRO EPZM RARE ASND

58
3 Things In Biotech, June 30: Aptose Gets Rolling Again; Tesaro Heads To China; Alexion Goes Big Across The Pond

2018-06-30 seekingalpha
Hello all, and welcome to another edition of 3 Things in Biotech. Today, I'm going to do something a little extra for you. I'm offering a sneak peek into what members of the Total Pharma Tracker get every day. If you like what you see and would like to get more ideas like this each day, consider becoming a subscriber!
TSRO AZN AZN BGNE

13
TESARO Draws $200 Million From Second Tranche of Non-Dilutive Term Loan Financing

2018-06-29 globenewswire
WALTHAM, Mass., June 29, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology focused biopharmaceutical company, announced today that it has drawn the $200 million second tranche under its term loan agreement with BIOPHARMA CREDIT PLC and BIOPHARMA CREDIT INVESTMENTS IV SUB LP, investment funds managed by Pharmakon Advisors, LP.
TSRO LNSTY

13
TSRO / TESARO, Inc. 8-K (Current Report)

2018-06-29 sec.gov
UNITED STATES
TSRO

11
TSRO / TESARO, Inc. 8-K (Current Report)

2018-06-29 sec.gov
UNITED STATES
TSRO

10
TESARO Enters Asset Purchase Agreement with TerSera® Therapeutics LLC for VARUBI® in the U.S. and Canada

2018-06-28 globenewswire
WALTHAM, Mass., June 28, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced that it has entered into an asset purchase agreement with TerSera Therapeutics LLC (TerSera) under which it will divest North American rights to the oral and intravenous formulations of VARUBI® (rolapitant). TerSera will be responsible for VARUBI in the U.S. and Canada, and TESARO will continue to commercialize VARUBY® in Europe and will retain rest of world rights under a sublicense from TerSera.
TSRO

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CUSIP: 881569107